Imfinzi (durvalumab) is approved in combination with chemotherapy as first line treatment of adult patients with extensive-stage small cell lung cancer (SCLC). A recent double-blind, randomized, placebo-controlled phase 3 study published in the New England Journal of Medicine demonstrates efficacy and safety of durvalumab after chemoradiotherapy in limited-stage SCLC. Read more about the recent FDA approval here.
The trial examined the effectiveness of the immunotherapy drug durvalumab, with or without tremelimumab, as an adjuvant treatment following standard chemotherapy and radiation.
ADRIATIC Study Highlights
Patients receiving durvalumab experienced significantly longer overall survival compared to those in the placebo group. The median survival was 55.9 months for the durvalumab group versus 33.4 months for the placebo group. Additionally, progression-free survival was extended to 16.6 months with durvalumab, compared to 9.2 months with placebo.
The incidence of severe adverse events was similar between the durvalumab and placebo groups, with pneumonitis occurring in a small percentage of patients in both groups.
What’s Next
The trial results indicate that adjuvant therapy with durvalumab significantly improved survival outcomes for patients with limited-stage SCLC. Further analysis of the combination therapy with tremelimumab is ongoing.
More Reading
Overview of Small Cell Lung Cancer
Join the Conversation on CancerConnect!
Reference:
Cheng Y, Spigel DR, Cho BC, Laktionov KK, et al; ADRIATIC Investigators. Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer. N Engl J Med. 2024 Oct 10;391(14):1313-1327.
